The effect of interleukin-22 treatment on autoimmune diabetes in the NOD mouse
Danielle J Borg, Ran Wang, Lydia Murray, Hui Tong, Raymond J Steptoe, Michael A McGuckin, Sumaira Z Hasnain
Diabetologia | SPRINGER | Published : 2017
AIMS/HYPOTHESIS: The aim of this study was to determine whether therapy with the cytokine IL-22 could be used to prevent the development of, or treat, autoimmune diabetes in the NOD mouse. METHODS: Six-week-old NOD mice were administered bi-weekly either recombinant mouse IL-22 (200 ng/g) or PBS (vehicle control) intraperitoneally until overt diabetes was diagnosed as two consecutive measurements of non-fasting blood glucose ≥ 11 mmol/l. At this time, NOD mice in the control arm were treated with LinBit insulin pellets and randomised to bi-weekly therapeutic injections of either PBS or IL-22 (200 ng/g) and followed until overt diabetes was diagnosed, as defined above. RESULTS: IL-22 therapy ..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) Project
Awarded by Australian Research Council (ARC) Future Fellowship
Awarded by NHMRC
DJB was supported by National Health and Medical Research Council (NHMRC) Project Grant APP1081473 and the Mater Foundation. RJS was a recipient of an Australian Research Council (ARC) Future Fellowship (FT110100372). MAM was supported by an NHMRC Principal Research Fellowship. SZH was supported by a UQ Fellowship. This work was partly funded by the NHMRC project grant application APP1081473, the Mater Foundation, UQ Foundation of Research Excellence Award and the Jared Purton Award by Australasian Society for Immunology to SZH. The Translational Research Institute is supported by a grant from the Australian Government.